(Q35016583)

English

Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells (English)

1 reference

Europe PubMed Central

5 August 2017

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

childhood acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Na-Na Wang

1

1 reference

Europe PubMed Central

5 August 2017

Zhi-Heng Li

2

1 reference

Europe PubMed Central

5 August 2017

He Zhao

3

1 reference

Europe PubMed Central

5 August 2017

Yan-Fang Tao

4

1 reference

Europe PubMed Central

5 August 2017

Li-Xiao Xu

5

1 reference

Europe PubMed Central

5 August 2017

Jun Lu

6

1 reference

Europe PubMed Central

5 August 2017

Lan Cao

7

1 reference

Europe PubMed Central

5 August 2017

Xiao-Juan Du

8

1 reference

Europe PubMed Central

5 August 2017

Li-Chao Sun

9

1 reference

Europe PubMed Central

5 August 2017

Wen-Li Zhao

10

1 reference

Europe PubMed Central

5 August 2017

Pei-Fang Xiao

11

1 reference

Europe PubMed Central

5 August 2017

Fang Fang

12

1 reference

Europe PubMed Central

5 August 2017

Guang-Hao Su

13

1 reference

Europe PubMed Central

5 August 2017

Yan-Hong Li

14

1 reference

Europe PubMed Central

5 August 2017

Gang Li

15

1 reference

Europe PubMed Central

5 August 2017

Yi-Ping Li

16

1 reference

Europe PubMed Central

5 August 2017

Yun-Yun Xu

17

1 reference

Europe PubMed Central

5 August 2017

Hui-Ting Zhou

18

1 reference

Europe PubMed Central

5 August 2017

Yi Wu

19

1 reference

Europe PubMed Central

5 August 2017

Mei-Fang Jin

20

1 reference

Europe PubMed Central

5 August 2017

Lin Liu

21

1 reference

Europe PubMed Central

5 August 2017

Jian Ni

22

1 reference

Europe PubMed Central

5 August 2017

Jian Wang

23

1 reference

Europe PubMed Central

5 August 2017

Shao-Yan Hu

24

1 reference

Europe PubMed Central

5 August 2017

Xue-Ming Zhu

25

1 reference

Europe PubMed Central

5 August 2017

Xing Feng

26

1 reference

Europe PubMed Central

5 August 2017

Jian Pan

27

1 reference

Europe PubMed Central

5 August 2017

language of work or name

0 references

publication date

7 January 2015

1 reference

Europe PubMed Central

5 August 2017

International Journal of Molecular Sciences

1 reference

Europe PubMed Central

5 August 2017

16

1 reference

Europe PubMed Central

5 August 2017

1266-1292

1 reference

Europe PubMed Central

5 August 2017

1

1 reference

Europe PubMed Central

5 August 2017

copyright license

Creative Commons Attribution 4.0 International

7 January 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Defining the ligand specificity of the deleted in colorectal cancer (DCC) receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

New agents: great expectations not realized

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

New targets in pediatric Acute Myeloid Leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

The role of quizartinib in the treatment of acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

The evolving landscape in the therapy of acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Novel agents and biomarkers for acute lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Novel therapies for children with acute myeloid leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Polo-like kinases inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Identification of novel, potent and selective inhibitors of Polo-like kinase 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Polo-like kinase 1 (Plk1) in non-melanoma skin cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Preclinical models for cell cycle-targeted therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

8 July 2018

Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011266

21 January 2018

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011266

21 January 2018

PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011266

21 January 2018

Polo-like kinases in AML.

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011266

21 January 2018

High-throughput real-time PCR.

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011266

21 January 2018

Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

25 October 2018

Plk1, a negative regulator of p21?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307303

25 October 2018

Identifiers

10.3390/IJMS16011266

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35016583&oldid=1858876770"